{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T02:36:02Z","timestamp":1740105362445,"version":"3.37.3"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.bbrc.2024.150616","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T06:24:32Z","timestamp":1724826272000},"page":"150616","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Overcoming cisplatin resistance in ovarian cancer: A novel approach via mitochondrial targeting peptide Pal-pHK-pKV"],"prefix":"10.1016","volume":"734","author":[{"given":"Yiqing","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongya","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ailin","family":"Gui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yichen","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aihua","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.bbrc.2024.150616_bib1","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1002\/cam4.2560","article-title":"Ovarian cancer: current status and strategies for improving therapeutic outcomes","volume":"8","author":"Chandra","year":"2019","journal-title":"Cancer Med."},{"issue":"12","key":"10.1016\/j.bbrc.2024.150616_bib2","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1080\/14737140.2017.1398088","article-title":"Optimizing treatment in recurrent epithelial ovarian cancer","volume":"17","author":"Corrado","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"5","key":"10.1016\/j.bbrc.2024.150616_bib3","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-17-0336","article-title":"Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment","volume":"25","author":"Van Zyl","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"issue":"1","key":"10.1016\/j.bbrc.2024.150616_bib4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40659-019-0243-6","article-title":"Berberine in combination with cisplatin induces necroptosis and apoptosis in ovarian cancer cells","volume":"52","author":"Liu","year":"2019","journal-title":"Biol. Res."},{"issue":"10","key":"10.1016\/j.bbrc.2024.150616_bib5","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1517\/14728222.2013.833607","article-title":"Targeting VDAC-bound hexokinase II: a promising approach for concomitant anti-cancer therapy","volume":"17","author":"Krasnov","year":"2013","journal-title":"Expert Opin. Ther. Targets"},{"issue":"6","key":"10.1016\/j.bbrc.2024.150616_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11060813","article-title":"Hexokinase 2 regulates ovarian cancer cell migration, invasion and stemness via FAK\/ERK1\/2\/MMP9\/NANOG\/SOX9 signaling cascades","volume":"11","author":"Siu","year":"2019","journal-title":"Cancers"},{"issue":"Pt 2","key":"10.1016\/j.bbrc.2024.150616_bib7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1042\/bj20031465","article-title":"In self-defence: hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death","volume":"377","author":"Azoulay-Zohar","year":"2004","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbrc.2024.150616_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.biocel.2017.12.010","article-title":"Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy","volume":"95","author":"Zhang","year":"2018","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"5","key":"10.1016\/j.bbrc.2024.150616_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052537","article-title":"PGC1\u03b1 promotes cisplatin resistance in ovarian cancer by regulating the HSP70\/HK2\/VDAC1 signaling pathway","volume":"22","author":"Li","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"30","key":"10.1016\/j.bbrc.2024.150616_bib10","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1039\/C9TB00629J","article-title":"Self-assembly of mitochondria-specific peptide amphiphiles amplifying lung cancer cell death through targeting the VDAC1-hexokinase-II complex","volume":"7","author":"Liu","year":"2019","journal-title":"J. Mater. Chem. B"},{"issue":"10","key":"10.1016\/j.bbrc.2024.150616_bib11","doi-asserted-by":"crossref","first-page":"570","DOI":"10.21037\/atm-22-2233","article-title":"Mitochondria-specific peptide amphiphiles induce mitochondrial dysfunction and peripheral T-cell lymphomas (PTCL) damage","volume":"10","author":"Sun","year":"2022","journal-title":"Ann. Transl. Med."},{"issue":"3","key":"10.1016\/j.bbrc.2024.150616_bib12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.bbrc.2024.150616_bib13","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ygyno.2016.06.013","article-title":"FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited","volume":"142","author":"Ataseven","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bbrc.2024.150616_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114205","article-title":"Therapeutic strategies to overcome cisplatin resistance in ovarian cancer","volume":"232","author":"Song","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"1 Suppl 2","key":"10.1016\/j.bbrc.2024.150616_bib15","first-page":"84","article-title":"Paclitaxel plus carboplatin in the treatment of ovarian cancer","volume":"26","author":"Ozols","year":"1999","journal-title":"Semin. Oncol."},{"issue":"33","key":"10.1016\/j.bbrc.2024.150616_bib16","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1200\/JCO.21.00334","article-title":"Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA)","volume":"39","author":"Hamanishi","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"3 Pt 2","key":"10.1016\/j.bbrc.2024.150616_bib17","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0090-8258(03)00467-0","article-title":"Clinical experience with topotecan in relapsed ovarian cancer","volume":"90","author":"Herzog","year":"2003","journal-title":"Gynecol. Oncol."},{"issue":"12","key":"10.1016\/j.bbrc.2024.150616_bib18","first-page":"8277","article-title":"A lipidated peptide with mitochondrial membrane localization in human A549 lung cells: from enhanced cell-penetrating properties to biological activity mechanism","volume":"4","author":"Zhang","year":"2021"},{"issue":"2","key":"10.1016\/j.bbrc.2024.150616_bib19","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bbabio.2006.11.013","article-title":"VDAC1 serves as a mitochondrial binding site for hexokinase in oxidative muscles","volume":"1767","author":"Anflous-Pharayra","year":"2007","journal-title":"Biochim. Biophys. Acta"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X24011525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X24011525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T19:31:40Z","timestamp":1732649500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X24011525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":19,"alternative-id":["S0006291X24011525"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2024.150616","relation":{},"ISSN":["0006-291X"],"issn-type":[{"type":"print","value":"0006-291X"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming cisplatin resistance in ovarian cancer: A novel approach via mitochondrial targeting peptide Pal-pHK-pKV","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2024.150616","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"150616"}}